Opinion

Video

Final Thoughts

Author(s):

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,Amir Ali, PharmD, BCOP

The panel discussion concludes with final thoughts on the future landscape of newly diagnosed multiple myeloma.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
3 experts are featured in this series.
Related Content
Patient self-administering subcutaneous injection | Image Credit: © - stock.adobe.commanusapon
September 4th 2025

Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma

Alexandra Gerlach, Associate Editor
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
September 4th 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
CAR T-cell therapy injected into tumor cell 3D visualization | Image Credit: © john - stock.adobe.com
September 4th 2025

Targeted Therapy Brings Remission in Patient With CAR-Positive T-Cell Lymphoma

Alexandra Gerlach, Associate Editor
Pharmacy Focus: Oncology Edition
September 4th 2025

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

Gloved hand holding blood sample | Image Credit: © Csaba Deli - stock.adobe.com
September 4th 2025

Blood Test Could Replace Bone Marrow Biopsies in Multiple Myeloma

Alexandra Gerlach, Associate Editor
Abnormal plasma cell or b-cell in multiple myeloma emitting paraprotein 3d illustration | Image Credit: LASZLO | stock.adobe.com
September 4th 2025

Can Cilta-Cel Redefine Outcomes in Multiple Myeloma?

Alexandra Gerlach, Associate Editor
© 2025 MJH Life Sciences

All rights reserved.